Project description:We sorted the MDSCs from the bone marrows of B16-F10 tumor-bearing mice and the naive mice. In addition, we cultured MDSCs in vitro to determine the effect of DOX (5µM).
Project description:Purpose: Next-generation sequencing (NGS) has revolutionized systems-based analysis of cellular pathways. The goals of this study are to compare CD84 activated to control treated primary human G-MDSCs from multiple myeloma patients transcriptome profiling (RNA-seq) to understand the role of CD84 on these cells Methods: mRNA profiles from sorted G-MDSCs from patient bone marrow samples were generated by deep sequencing, in triplicate, using a bulk adaptation of the MARS-Seq protocol.
Project description:Purpose: Next-generation sequencing (NGS) has revolutionized systems-based analysis of cellular pathways. The goals of this study are to compare CD84 activated to control treated primary human M-MDSCs from multiple myeloma patients transcriptome profiling (RNA-seq) to understand the role of CD84 on these cells Methods: mRNA profiles from sorted M-MDSCs from patient bone marrow samples were generated by deep sequencing, in triplicate, using a bulk adaptation of the MARS-Seq protocol.
Project description:Myeloid-derived suppressor cells (MDSCs) as a population of myeloid cells enriched in cancer patients with immunosuppressive function. Further studies have determined that MDSCs are comprised of two groups: polymorphonuclear-MDSCs (G-MDSCs) and monocytic-MDSCs (M-MDSCs). We used a microbeads kit (Miltenyi) to isolate G-MDSCs and M-MDSCs with markers Ly6c2-Ly6g+CD11b+ and Ly6c2+Ly6g-CD11b+, respectively. And then using bulk RNA-seq to anlysis the enrichment gene expression in G-or M-MDSC which from wild type, APCmin mutant adenoma and immune deffiency mice.
Project description:Murine MDSCs isolated from the spleens of Lewis lung carcinoma mice were treated with or without WGP, and then miRNA array was used to analyze the differentailly expressed miRNAs. Murine MDSCs were isolated from the spleens of Lewis lung carcinoma tumor-bearing mice, and the sorted MDSCs were stimulated with or without 100 µg/ml WGP for 24 h. Then, the total RNA was extracted to perform miRNA array to analyze the differentially expressed miRNAs in MDSCs treated with or without WGP
Project description:Myeloid-derived suppressor cells (MDSCs) are increased by tumor-derived factors and suppress anti-tumor immunity. MDSCs obtained at a late time point after tumor injection had stronger suppressive activity than MDSCs obtained at an early time point, as measured by T cell proliferation assays. To find factors in MDSCs that change during tumor growth, we analyzed gene expression profiles from MDSCs at different time points after tumor injection. We found that immune response-related genes were down-regulated, but pro-tumor function-related genes were up-regulated in both Mo-MDSCs and PMN-MDSCs at the late time point. Among differentially expressed genes, FK506 binding protein 51 (FKBP51), which is a member of the immunophilin protein family and plays a role in immunoregulation, was increased in the Mo- and PMN-MDSCs isolated from the late time points. Experiments using siRNA and a chemical inhibitor of FKBP51 revealed that FKBP51 contributes to the regulation of the suppressive function of MDSCs by increasing iNOS, ARG1, and ROS levels and enhancing NF-kappaB activity. Collectively, our data suggest that FKBP51 is a novel molecule that can be targeted to regulate the immunosuppressive function of MDSCs. To identify the factors that licensed MDSCs to be more suppressive as tumors grow, we analyzed gene expression profiles in the two subsets of MDSCs at different time points (3wks, 6wks) during tumor progression. CD11b+Ly-6C(high)Ly-6G(low) Mo-MDSCs and CD11b+Ly-6C(low)Ly-6G(high) PMN-MDSCs were sorted from pooled spleens of naïve mice and Her-2/CT26 tumor-bearing mice. Total RNA was purified and gene expression was analyzed by the Affymetrix GeneChip® Mouse Gene 1.0 ST Array.
Project description:This study is set out to identify EGCG transcriptional targets in 4T1 breast cancer mediated myeloid-derived suppressor cells (MDSCs) in vitro. MDSCs were sorted from the spleens of 4T1-bearing mice and cultured with EGCG for 6h. RNA was extracted from either the Control group or EGCG group and for RNA-sequence.
Project description:The macrolide rapamycin is known for its immunosuppressive properties since it inhibits mTOR (mammalian target of rapamycin), which activity affects differentiation and functions of various innate and adaptive immune cells involved in graft-versus-host disease development. Since rapamycin procures immunosuppressive effects on the immune response, rapamycin is an attractive candidate for graft-versus-host disease prevention after allogeneic bone marrow transplantation. Recently, an activating effect of rapamycin on the function of myeloid-derived suppressor cells (MDSCs), a subset of immune suppressive cells of myeloid origin was reported. However, the effect of rapamycin treatment on MDSCs induction and function in the management of graft-versus-host disease is largely unknown. We used an MHC class I and II mismatched parent into F1 bone marrow transplantation mouse model to elucidate the mechanisms of rapamycin on MDSCs in the context of graft-versus-host disease prevention. To define the impact of rapamycin therapy on MDSCs gene expression profile, we performed mircoarray analysis and compared gene expression profiles of ex vivo isolated MDSCs from rapamycin and PBS treated mice
